Last reviewed · How we verify
NCT05961462
Effects of Exercise Training on Patients With Long COVID-19
NA trial testing Exercise training in Long COVID-19 in 24 participants. Completed in 30 August 2023.
30 July 2023
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 10 January 2023 |
| Primary completion | 30 July 2023 |
| Estimated completion | 30 August 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Exercise training
Conditions studied
- Long COVID-19 — all drugs for Long COVID-19 →
Sponsor
Guangdong Provincial People's Hospital
Who can join
Adults 18 to 75, any sex, with Long COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effects of Exercise training on Patients With Long COVID-19, is a single-center, randomized, controlled trial designed to evaluate the effects of 4- week aerobic exercise administered to patients with long COVID-19 symptoms. The main outcome is cardiopulmonary fitness and long COVID-19 symptom improvement. Quality of life, depression, anxiety, insomnia status and perceived stress will also be assessed before and after the exercise program.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of aerobic training on cardiopulmonary fitness in patients with long COVID-19: a randomized controlled trial.
Bai B, Xu M, Zhou H, Liao Y, et al · · 2024 · cited 4× · PMID 39363376 · DOI 10.1186/s13063-024-08473-3
Verify or expand the search:
- PubMed search for NCT05961462
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Exercise training
Trials testing the same drug.
- NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
- NCT07513987 — IMPACT: Immune and Musculoskeletal Physiological Adaptations to Combined Exercise Training & Nutrition · NA · not yet recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
- NCT07341711 — Long-term Adaptations of Skeletal Muscle After Hybrid Training. · NA · not yet recruiting
- NCT07300332 — Exercise Training and Vitamin D Metabolism · NA · recruiting
Other recruiting trials for Long COVID-19
Currently open trials in the same condition.
- NCT06960928 — Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19 · Phase 3 · recruiting
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06404099 — RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia) · Phase 2 · active not recruiting
- NCT06404112 — RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD) · Phase 2 · active not recruiting
- NCT07005947 — Long COVID-19 Cutaneous Signatures: An ARPA Funded Research Project · active not recruiting
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05961462 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961462.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing